← Jazz Pharmaceuticals plc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Net Income (Loss) Attributable to Parent | $396.8m | $487.8m | $447.1m | $523.4m | $238.6m | ($329.7m) | ($224.1m) | $414.8m | $560.1m | ($356.1m) | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $396.8m | $487.8m | $447.1m | — | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 | $0 | — | — | — | — | — | — | — | — | |
| Depreciation, Depletion and Amortization | $11.8m | $13.1m | $15.2m | $15.3m | $18.7m | $26.7m | $30.3m | $30.4m | $32.8m | $41.6m | |
| Depreciation | $11.8m | $13.1m | $15.2m | $15.3m | $18.7m | $26.7m | $30.3m | $30.4m | $32.8m | $41.6m | |
| Amortization of Debt Issuance Costs | — | — | — | — | — | — | — | $4.2m | — | — | |
| Amortization of Debt Issuance Costs and Discounts | $22.1m | $30.0m | $44.0m | $46.4m | $56.7m | — | — | — | — | — | |
| Amortization of Intangible Assets | $102.0m | $152.1m | $201.5m | $354.8m | $259.6m | $525.8m | $599.2m | $608.3m | $627.3m | $654.7m | |
| Deferred Income Tax Expense (Benefit) | ($41.2m) | ($225.6m) | ($88.8m) | ($236.6m) | ($136.9m) | $69.2m | ($292.3m) | ($260.2m) | ($208.3m) | ($445.0m) | |
| Deferred Other Tax Expense (Benefit) | ($13.7m) | ($19.1m) | ($34.5m) | ($37.2m) | ($73.6m) | ($28.6m) | ($11.1m) | ($9.0m) | ($11.5m) | ($13.6m) | |
| Share-based Payment Arrangement, Noncash Expense | $98.8m | $106.9m | $102.4m | $110.6m | $121.0m | $189.0m | $222.0m | $226.8m | $248.0m | $291.1m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | $21.2m | $18.6m | $17.9m | $16.7m | $16.9m | $35.6m | $45.4m | $51.0m | $57.8m | $75.2m | |
| Share-based Payment Arrangement, Expense | $98.8m | $106.9m | $102.4m | $110.6m | $121.0m | $189.0m | $222.0m | $226.8m | $248.0m | $291.1m | |
| Impairment of Intangible Assets, Finite-lived | — | — | — | — | — | — | — | $0 | $0 | — | |
| Gain (Loss) on Disposition of Assets | — | — | ($655k) | ($21k) | — | — | — | — | — | — | |
| Gain (Loss) on Disposition of Business | — | — | — | — | — | — | ($37.7m) | $0 | $0 | — | |
| Gain (Loss) on Disposition of Property Plant Equipment | ($47k) | ($473k) | — | — | — | $0 | $0 | $61.0m | $0 | $0 | |
| Income (Loss) from Equity Method Investments | ($379k) | ($1.0m) | ($2.2m) | ($4.1m) | ($3.0m) | ($714k) | ($9.9m) | ($3.0m) | ($1.7m) | ($732k) | |
| Income Tax Expense (Benefit) | $135.2m | ($47.7m) | $80.2m | ($73.2m) | $33.5m | $216.1m | ($158.6m) | ($119.9m) | ($91.4m) | ($272.4m) | |
| Changes in operating assets and liabilities: | |||||||||||
| Additional Financial Items | |||||||||||
| Increase (Decrease) in Accounts Receivable | $25.6m | ($12.3m) | $40.1m | $92.3m | $38.6m | $92.7m | $90.1m | $51.9m | $21.1m | $106.3m | |
| Increase (Decrease) in Inventories | $17.0m | $8.7m | $18.5m | $32.8m | $30.5m | $48.9m | $49.6m | $13.4m | $45.5m | $86.0m | |
| Increase (Decrease) in Accounts Payable | $361k | $214k | $17.0m | $4.8m | ($18.9m) | $57.0m | ($11.2m) | $9.6m | ($20.1m) | $39.9m | |
| Foreign Currency Transaction Gain (Loss), before Tax | $3.4m | ($10.0m) | ($6.9m) | ($5.8m) | ($3.3m) | ($4.3m) | ($19.0m) | $8.8m | ($8.2m) | ($2.6m) | |
| Goodwill | $893.8m | $947.5m | $927.6m | $920.0m | $958.3m | $1.8b | $1.7b | $1.8b | $1.7b | $1.8b | |
| Investment Income, Interest | — | — | — | $20.5m | $11.1m | $1.8m | $11.5m | $65.1m | $106.3m | $85.8m | |
| Operating Expenses | $896.3m | $1.1b | $1.3b | — | — | — | — | — | — | — | |
| Net Cash Provided by (Used in) Operating Activities | $590.5m | $693.1m | $798.9m | $776.4m | $899.6m | $778.5m | $1.3b | $1.1b | $1.4b | $1.4b | |
| Cash flows from investing activities: | |||||||||||
| Payments to Acquire Property, Plant, and Equipment | $7.8m | $28.9m | $20.4m | $40.1m | $15.0m | $27.6m | $29.0m | $24.0m | $38.1m | $58.8m | |
| Payments to Acquire Businesses, Net of Cash Acquired | $1.5b | $0 | $0 | — | — | $6.2b | $0 | $0 | — | — | |
| Payments to Acquire Investments | $65.3m | $385.0m | $1.2b | $917.1m | $2.4b | $26.8m | $61.0m | $390.1m | $1.3b | $1.8b | |
| Net Cash Provided by (Used in) Investing Activities | ($1.7b) | ($268.9m) | ($394.5m) | ($155.3m) | ($1.0b) | ($5.2b) | ($446.2m) | ($163.1m) | ($508.2m) | ($1.5b) | |
| Cash flows from financing activities: | |||||||||||
| Payments for Repurchase of Common Stock | $278.3m | $98.8m | $523.7m | $301.4m | $146.5m | $0 | $54k | $269.8m | $311.4m | $125.0m | |
| Net Cash Provided by (Used in) Financing Activities | $541.0m | ($409.1m) | ($479.1m) | ($293.7m) | $528.1m | $4.0b | ($529.5m) | ($305.3m) | $20.5m | ($873.4m) | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($5.0m) | $5.0m | ($1.7m) | $366k | $374k | ($3.2m) | ($6.2m) | $1.1m | ($1.7m) | $6.6m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($5.0m) | $5.0m | ($1.7m) | $327.7m | $420.4m | ($466.3m) | $290.0m | $624.8m | $906.6m | ($1.0b) | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | $637.3m | $1.1b | $591.4m | $881.5m | $1.5b | $2.4b | $1.4b | |
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $39.9m | $44.6m | $42.7m | $43.0m | $42.5m | $138.3m | $270.7m | $333.1m | $314.8m | $248.6m | |
| Income Taxes Paid, Net | $160.3m | $174.1m | $164.2m | $183.6m | $226.8m | $271.2m | $94.7m | $177.9m | $114.9m | $121.8m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.